An organic aluminum sol and a preparation method thereof related to chemical technology fields. Organic mixed acids are used to react with aluminum powder to prepare organic aluminum sol as a precursor for preparing alumina fiber. The aluminum powder, formic acid, and oxalic acid are used as raw materials, the oxalic acid and the formic acid are firstly mixed to be even according to a preset ratio to obtain a mixed acid solution, and the aluminum powder is then completely reacted with the mixed acid solution to obtain an aluminum carboxylate solution under a condensation reflux condition, and the aluminum carboxylate solution is finally filtered to obtain the aluminum carboxylate sol that is clear and transparent. A chemical formula of a composition of the organic aluminum sol is expressed as: Al(OH)x(HCOO)y(COO—COO)z, wherein 0
B01J 13/00 - Chimie des colloïdes, p. ex. production de substances colloïdales ou de leurs solutions, non prévue ailleursFabrication de microcapsules ou de microbilles
B05D 1/00 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces
A transfer method for micro flip chips includes forming a first bonding member on a surface of one side of a second electrical connection piece of each of a plurality of micro flip chips facing away from a temporary substrate to which they are adhered. The micro flip chips are transferred onto a drive substrate. The second electrical connection pieces of the micro flip chips are connected to a corresponding one of first electrical connection pieces of the drive substrate via the first bonding members. The micro flip chips are inspected to determine bad point positions of defective chips on the drive substrate. The first bonding member is irradiated at each bad point position by laser and the defective chip is removed. The method ensures stable bonding between the micro flip chips and the drive substrate and prevents the first electrical connection pieces from being damaged by laser irradiation.
The present invention relates to the field of molecular virology and immunology, in particular to the field of hepatitis B virus (HBV) infection treatment. In particular, the present invention relates to an epitope peptide (or a variant thereof) capable of treating a hepatitis B virus infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and an antibody (e.g. a nanobody) for the epitope peptide. The epitope peptide and antibody of the present invention can be used to prevent and/or treat HBV infection or a disease related to HBV infection (e.g. hepatitis B), for reducing the serum level of HBV DNA and/or HBsAg in a subject (e.g. a human), or for activating a subject (e.g. a chronic HBV infected person or a chronic hepatitis B patient) against HBV humoral immune response.
The present invention relates to the field of genetic engineering. Disclosed is a universal nucleic acid detection platform, which is a universal nucleic acid detection platform on the basis of CRISPR-Cas9.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
5.
NUCLEOTIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF, NUCLIDE TARGETING PROBE, PREPARATION METHOD THEREFOR AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION
The present invention relates to the technical field of biomedicine, and particularly relates to a nucleotide compound, a preparation method therefor and a use thereof, a nuclide targeting probe, a preparation method therefor and a use thereof, and a pharmaceutical composition. The nucleotide compound and a nuclide labeled complex provided in the present invention have excellent in-vivo biological properties, high specific uptake in lesions having high expression of CD73 protein, a high target/non-target ratio and a low non-specific background. The characteristics can reduce unnecessary radioactive damage to normal tissues and organs, and are extremely suitable for the diagnosis and treatment of tumors. In addition, the nuclide targeting probe can also be used in combination with other immune checkpoint inhibitors (such as PD-1/PD-L1 monoclonal antibodies) for combined treatment. In addition, the nuclide targeting probe performs visual quantitative analysis on CD73 dynamic expression in a tumor microenvironment by means of nuclear medicine imaging, thereby overcoming the defects of wrong sampling and poor accuracy of conventional detection methods.
C07H 19/20 - Radicaux purine avec le radical saccharide estérifié par des acides phosphoriques ou polyphosphoriques
C07H 19/207 - Radicaux purine avec le radical saccharide estérifié par des acides phosphoriques ou polyphosphoriques les acides phosphoriques ou polyphosphoriques étant estérifiés par un autre composé hydroxylique, p. ex. les dinucléotides de la flavine-adénine ou de la nicotinamide-adénine
C07H 19/23 - Radicaux hétérocycliques contenant au moins deux hétérocycles condensés entre eux ou condensés avec un système carbocyclique commun, non prévus dans les groupes
A61K 31/70 - Hydrates de carboneSucresLeurs dérivés
A61K 31/7052 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
255) catalyst and tetrahydrofuran at a ratio of (0.06-0.25 g):(0.025-0.075 g):10 mL to a reactor, replacing air with hydrogen, and catalyzing 5-hydroxymethylfurfural to selectively synthesize 5-methylfurfural. The reaction conditions are as follows: the reaction temperature is 100-160ºC, the hydrogen pressure is 0.1-3 MPa, the stirring speed is 400-800 rpm, and the reaction time is 1-4 hours. In the present invention, the nickel/niobium pentoxide, which contains oxygen vacancies, is used as the catalyst, and the catalyst is not only simple in terms of preparation method, low in terms of price and high in terms of catalytic activity and stability, but can also effectively and selectively hydrogenate 5-hydroxymethylfurfural to directly prepare a single product, i.e., 5-methylfurfural.
B01J 37/10 - Traitement thermique en présence d'eau, p. ex. de vapeur d'eau
C07D 307/46 - Atomes d'oxygène liés par des liaisons doubles ou deux atomes d'oxygène liés par des liaisons simples au même atome de carbone
7.
GLUTAMIC ACID UREA COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF, NUCLIDE TARGETING PROBE AND PREPARATION METHOD THEREFOR AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION
The present invention relates to the technical field of biomedicine, and particularly relates to a glutamic acid urea compound and a preparation method therefor and a use thereof, a nuclide targeting probe and a preparation method therefor and a use thereof, and a pharmaceutical composition. The glutamic acid urea compound and the nuclide targeting probe provided by the present invention have excellent in-vivo biological performance, high specific uptake in lesions with high expression of PSMA protein, a high target-nontarget ratio, low non-specific background activity, and remarkably enhanced tumor uptake and retention time, are suitable for nuclide therapy and imaging of tumors, can reduce unnecessary radioactive damage to normal tissues and organs, can overcome the defects of low uptake and short retention time in small-molecule PSMA targeting organs, improve the PSMA targeting nuclide treatment and imaging effects, and have the potential of clinical popularization and application.
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
GLUTAMIC ACID -UREA COMPOUND, PREPARATION METHOD AND USE THEREOF, NUCLIDE-TARGETED PROBE, PREPARATION METHOD AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION
Provided is a glutamic acid (Glu)-urea compound and a preparation method and use thereof. The Glu-urea compound and the nuclide-targeted probe have excellent in vivo biological properties and show a high specific uptake in lesions with high expression of a prostate-specific membrane antigen (PSMA) protein. The compound and probe have a high target/non-target ratio, low non-specific background activity, and significantly-enhanced tumor uptake and retention time. The compound and probe are suitable for use in the nuclide therapy and imaging of tumors, and can also reduce unnecessary radiation damage to normal tissues and organs. The compound and probe can also overcome the shortcomings such as low target organ uptake and short retention time of small-molecule PSMA, and improve the effects of PSMA-targeted nuclide therapy and imaging, thus exhibiting a potential to be widely used in clinical applications.
A resonant ultrasound spectroscopy-based nondestructive testing apparatus and method for a lithium battery. The apparatus comprises a sweep-frequency signal generation module, a power amplification module, a transmitting ultrasonic transducer, a receiving ultrasonic transducer, a pre-amplification module, a data acquisition module and a lock-in amplification module. The testing method comprises: amplifying the power of a sweep-frequency signal to serve as an excitation signal of a transmitting transducer, and using same to perform lock-in processing on a signal received by a receiving transducer, so as to obtain transmitted and reflected wave-based resonant ultrasound spectra at different positions of a lithium battery; identifying a plurality of resonance frequencies from the resonant ultrasound spectra, and analyzing resonant ultrasound spectrum features and the passband and stopband features within a resonant ultrasound spectrum signal; extracting from the resonant ultrasound spectrum signal amplitude information of transmitted waves at different frequency points to obtain an amplitude cloud map of the transmitted waves of the lithium battery at the plurality of frequency points and a mechanical quality factor of the lithium battery; and detecting a failure state of the lithium battery, and quantitatively evaluating the SoC of the lithium battery.
G01N 29/12 - Analyse de solides en mesurant la fréquence ou la résonance des ondes acoustiques
G01N 29/46 - Traitement du signal de réponse détecté par analyse spectrale, p. ex. par analyse de Fourier
G01N 29/48 - Traitement du signal de réponse détecté par comparaison d'amplitude
G01N 29/44 - Traitement du signal de réponse détecté
G01R 31/387 - Détermination de la capacité ampère-heure ou de l’état de charge
G01R 31/378 - Dispositions pour le test, la mesure ou la surveillance de l’état électrique d’accumulateurs ou de batteries, p. ex. de la capacité ou de l’état de charge spécialement adaptées à un type de batterie ou d’accumulateur
10.
IMMUNE-ENHANCING ALUMINUM EMULSION, AND PREPARATION METHOD THEREFOR AND USE THEREOF
An immune-enhancing aluminum emulsion, and a preparation method therefor and a use thereof. Specifically provided are an oil-in-water emulsion containing an inorganic salt and a preparation method for the oil-in-water emulsion. Also provided are a vaccine adjuvant comprising the oil-in-water emulsion, a vaccine composition and a pharmaceutical composition. Also provided is a use of the oil-in-water emulsion as a vaccine adjuvant.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
11.
CITRULLINATED SETDB1 POLYPEPTIDE AND USE THEREOF IN DIAGNOSIS OF RHEUMATOID ARTHRITIS
A method for diagnosing rheumatoid arthritis on the basis of the level of an anti-citrullinated SETDB1 antibody, and a kit for use in the method. Provided are a polypeptide for the above-mentioned diagnosis of the level of an anti-citrullinated SETDB1 antibody, and the use thereof in the diagnosis of rheumatoid arthritis.
C07K 4/12 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'animauxPeptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'humains
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
12.
PREPARATION METHOD FOR CHIRAL DIHYDROTHIENOPYRIMIDINE SULFOXIDE AND USE THEREOF, AND 2- AND 4-SUBSTITUTED COMPOUND OF CHIRAL DIHYDROTHIENOPYRIMIDINE SULFOXIDE
Provided are a preparation method for a chiral dihydrothienopyrimidine sulfoxide and a use thereof, and 2- and 4-substituted compound of the chiral dihydrothienopyrimidine sulfoxide. The preparation method for the chiral dihydrothienopyrimidine sulfoxide comprises: oxidizing 2,4-disubstituted-6,7-dihydrothienopyrimidine into (R)-2,4-disubstituted-6,7-dihydrothieno[3,2-d]pyrimidine sulfoxide by means of an oxidizing agent under the action of a chiral biguanide catalyst and a molybdate catalyst. The reaction conditions are mild, the reaction process is green and environment-friendly, industrial production is facilitated, and the reaction product has excellent enantioselectivity.
B01J 31/02 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques
B01J 31/34 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant en outre des composés métalliques inorganiques non prévus dans les groupes du chrome, du molybdène ou du tungstène
An antimicrobial peptide Bolespleenin of Boleophthalmus pectinirostris and application thereof, and an amino acid sequence of the antimicrobial polypeptide Bolespleenin is shown in SEQ ID NO.01.
Provided is a novel vaccine delivery system. The novel vaccine delivery system can realize lymph node co-delivery of an antigen and an adjuvant, thereby effectively enhancing the immune-promoting effect of the adjuvant, and significantly improving the antigen-specific immune response; moreover, the vaccine delivery system is superior to an oil-type composite adjuvant system that is commonly clinically used. Particularly, the vaccine delivery system exhibits a significant anti-tumor effect in tumor prevention and treatment, thereby providing a new idea for development and application of a novel vaccine delivery system.
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
An OTUB2 inhibitor and the use thereof in tumor immunity, specifically, the use and method of OTUB2 inhibitor for enhancing anti-tumor immune response, for reducing tumor immunosuppression, and/or for treating tumors. The present application further comprises a small molecule inhibitor targeting OTUB2.
The present invention relates to a luminescent material and a Mini-LED device prepared by the luminescent material; the luminescent material is formed by compounding a porous material and a luminescent substance, and has a chemical formula of: N@AX·aPbX2·bMX2, where N denotes the porous material, @ denotes compounding, and AX·aPbX2·bMX2 denotes the luminescent substance, where A is at least one of Cs and Rb, X is at least one of Cl, Br, and I; M is at least one of Mg, Ca, Sr, Ba, Zn, and Cu. and 0.7
C09K 11/66 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du germanium, de l'étain ou du plomb
C09K 11/55 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du béryllium, du magnésium, des métaux alcalins ou métaux alcalino-terreux
C09K 11/61 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du fluor, du chlore, du brome, de l'iode ou des halogènes non spécifiés
17.
ANTIBODY FOR RECOGNIZING RSV PRE-F PROTEIN AND USE THEREOF
The present invention relates to the field of immunology and molecular virology, and in particular relates to the field of the prevention and treatment of RSV. Specifically, provided are a monoclonal antibody capable of specifically binding to a new epitope between an Ø epitope and a V epitope on a pre-F protein or a new epitope between an II epitope and a V epitope, and the use thereof in the detection, prevention and/or treatment of RSV infection and/or diseases caused by the infections.
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 31/14 - Antiviraux pour le traitement des virus ARN
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
18.
HOLLOW SPONGE SPICULE, AND PREPARATION METHOD THEREFOR AND USE THEREOF
A hollow sponge spicule, and a preparation method therefor and a use thereof. Specifically disclosed are a preparation method for a hollow sponge spicule using a sponge Haliclona sp. spicule and the like as basic raw materials, and characterization data after treatment with the preparation method. According to the preparation method, an alkaline solution prepared from sodium hydroxide is used as a treating agent, and a sponge spicule is soaked and shaken, so as to achieve the purpose of reacting the alkaline solution with a silicon substance contained in the spicule, thereby generating a hollow channel in the spicule. Thus, the efficiency of transdermal drug delivery is improved, the drug utilization rate is improved, and more efficient, stable and safe transdermal absorption of a series of biomacromolecules such as drugs and cosmetic active components is promoted.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/46 - Ingrédients de constitution indéterminée ou leurs produits de réaction, p. ex. peau, os, lait, fibre de coton, coquille d’œuf, fiel de bœuf ou extraits de plante
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
A61Q 19/00 - Préparations pour les soins de la peau
19.
PENETRATION-ENHANCING COMPOSITION COMPRISING IONIC LIQUIDS AND SPONGE SPICULES, ACTIVE COMPOSITION COMPRISING PENETRATION-ENHANCING COMPOSITION, AND USES
The present invention relates to the technical field of medicines, and particularly relates to the synthesis and use of ionic liquids and percutaneous drug delivery. Disclosed are a penetration-enhancing composition comprising ionic liquids and sponge spicules, an active composition comprising the penetration-enhancing composition, and uses. According to the present invention, several ionic liquids having biological activity are synthesized, and as green solvents, have good solubility for poorly soluble active ingredients, and when the ionic liquids are used in combination with the sponge spicules, a good penetration-enhancing effect is achieved on percutaneous delivery of lipophilic substances by means of the synergistic effect of the ionic liquids and the sponge spicules, thereby greatly facilitating the percutaneous delivery of the poorly soluble active ingredients.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
A61K 8/36 - Acides carboxyliquesLeurs sels ou anhydrides
20.
GENERAL AFFINITY EPITOPE POLYPEPTIDE FOR HUMAN RHINOVIRUS, AND ANTIBODY AND USES THEREOF
The present invention belongs to the field of immunobiology, and relates to an epitope polypeptide, such as a general affinity epitope polypeptide of human rhinovirus, and the use thereof. The present invention further relates to an antibody capable of binding to the epitope polypeptide and the use thereof. The present invention further relates to the use of the affinity epitope polypeptide or the antibody in the preparation of drugs or in methods for treating and/or preventing and/or diagnosing human rhinovirus and/or identifying a titer of human rhinovirus and/or identifying a titer of a neutralizing antibody of human rhinovirus. The affinity epitope polypeptide and antibody can be used in drugs or methods for treating and/or preventing and/or diagnosing human rhinovirus and/or identifying a titer of human rhinovirus and/or identifying a titer of a neutralizing antibody of human rhinovirus.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/385 - Haptènes ou antigènes, liés à des supports
A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
21.
FLUORESCENCE ANALYSIS METHOD FOR LITHIUM ION DETERMINATION USING FREE-BASE PHTHALOCYANINE (FBPc) AS MOLECULAR PROBE
The present disclosure provides a fluorescence analysis method for lithium ion determination using free-base phthalocyanine (FBPc) as a molecular probe, and relates to the technical field of fluorescent probes. The method includes the following steps: adding an alkaline organic medium separately into a plurality of reaction vessels, and adding a phthalocyanine organic solution having a same volume as that of the alkaline organic medium; adding lithium ion organic solutions with increasing concentrations in sequence; diluting an obtained reaction system, allowing to stand to conduct a reaction, scanning a fluorescence spectrum of the reaction system, and determining a relative fluorescence intensity at a fluorescence peak. A determination principle is that in organic media, especially an alkaline organic medium, lithium ions can react with the FBPc to emit strong red fluorescence, and generation of the fluorescence has the remarkable characteristics of ultra-sensitivity and high specificity.
A prostate cancer high-specificity spectrum detection method and a cancer determination device. A prostate-specific antigen (PSA) and exosomes are used in combination for testing, the objective of distinguishing the PSA and the exosomes is achieved by means of a plasmon spectrum detection method, and a use in simpler and more rapid and accurate testing of the serum of prostate cancer patients is achieved.
G01N 21/25 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes
23.
METHOD FOR PREPARING 2,5-BISHYDROXYMETHYLFURAN USING 5-CHLOROMETHYLFURFURAL
A method for preparing 2,5-bishydroxymethylfuran using 5-chloromethylfurfural, the 5-chloromethylfurfural is transformed into the 2,5-bishydroxymethylfuran using a catalyst, a base neutralizer, sodium dithionite, and deionized water.
C07D 307/42 - Atomes d'oxygène liés par des liaisons simples
B01J 23/89 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe du cuivre ou des métaux du groupe du fer combinés à des métaux nobles
A PEN2 treatment method, use, and composition. The invention achieves using PEN2 as a target for developing a drug to activate AMPK, overcomes the difficulty in the prior art of directly using AMPK as a drug target, and has good application prospects.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
The present invention relates to the field of biomedicines, and relates to a use of a leucine-rich repeat kinase 2 (LRRK2) inhibitor and an oncolytic virus in tumor therapy, and a use of LRRK2 as a molecular marker in diagnosis of oncolytic therapy sensitivity. Specifically, the present invention provides a pharmaceutical combination comprising an LRRK2 inhibitor and an oncolytic virus, a pharmaceutical composition, a kit, and a use and method thereof for treating tumors. The present invention further provides a use and method of an LRRK2 inhibitor for enhancing the anti-tumor activity of an oncolytic virus or increasing the sensitivity of a tumor to the oncolytic virus. The present invention further provides a use and method of LRRK2 as a molecular marker in diagnosis of oncolytic therapy sensitivity.
Provided in the embodiments of the present application are a charge-discharge apparatus, a manufacturing method therefor, a battery cell, a battery and an electrical apparatus. The charge-discharge apparatus is used for implementing a charge-discharge function, and comprises a base body member (1), and an electronic device (2) provided on the base body member (1), the electronic device (2) and the base body member (1) being integrally formed.
H01M 10/42 - Procédés ou dispositions pour assurer le fonctionnement ou l'entretien des éléments secondaires ou des demi-éléments secondaires
H01M 10/48 - Accumulateurs combinés à des dispositions pour mesurer, tester ou indiquer l'état des éléments, p. ex. le niveau ou la densité de l'électrolyte
Provided is a method for preparing 2,5-hexanedione by using 5-chloromethylfurfural. 5-Chloromethylfurfural, a catalyst, polymethylhydrosiloxane, tetrahydrofuran, and water are added into a thick-wall pressure bottle, and the synthesis of 2,5-hexanedione from 5-chloromethylfurfural is catalyzed. The starting material 5-chloromethylfurfural can be directly prepared from biomass with high yield. The starting material polymethylhydrosiloxane is inexpensive, non-toxic, and stable. The reaction process is safe and environment-friendly. The product selectivity is high. The yield of 2,5-hexanedione is high. The method has industrial application value.
C07C 45/59 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogènePréparation des chélates de ces composés à partir de composés hétérocycliques avec l'oxygène comme unique hétéro-atome dans des cycles à cinq chaînons
C07C 49/12 - Cétones comportant plus d'un groupe cétone
The present invention provides fusion proteins of gE and gI (or variants thereof) that can be used for preventing or treating varicella-zoster virus infection, and use of such fusion proteins (or the variants thereof).
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
29.
COMPOSITE METAL MATERIAL AND LOW-TEMPERATURE SOLDER PASTE WITH HIGH THERMAL CONDUCTIVITY CONTAINING SAME
The present invention relates to a composite metal material and a low-temperature solder paste with high thermal conductivity containing the same. The composite metal material is a Cu core/Ag intermediate layer/Sn shell type metal powder (Cu@Ag@Sn) or a Cu core/Ni intermediate layer/Sn shell type metal powder (Cu@Ni@Sn) with a particle size of 20-60 μm. The low-temperature solder paste with high thermal conductivity is obtained by mixing the composite metal material with an Sn—Bi series alloy powder and a flux paste, can be used for welding of a variety of substrate, and is suitable for welding at a low temperature of lower than 150° C. The composite metal material of the present invention has a simple process, a low cost and high practicability, and poor heat dissipation and other problems of power devices after die bonding caused by low thermal conductivity of current solder pastes on the market are solved.
B23K 35/02 - Baguettes, électrodes, matériaux ou environnements utilisés pour le brasage, le soudage ou le découpage caractérisés par des propriétés mécaniques, p. ex. par la forme
B22F 1/05 - Poudres métalliques caractérisées par la dimension ou la surface spécifique des particules
A reusable protective clothing includes a one-piece protective suit which includes integrated top and trousers attached with gloves and shoe covers, and a protective headpiece having a face shield. A front side of the protective headpiece is provided with a full-vision goggle with 180-degree field of view, the full-vision goggle is integrated with the face shield, a back side of the protective headpiece is provided with a protective hood made of a material of the one-piece protective suit, the protective hood is integrated with the top, the front side of the protective headpiece is provided with an air vent for a mouth and a nose configured according to facial features of a wearer, and an outer side of the protective headpiece is provided with ear-shaped hooks. The protective clothing is designed according to application environment and medical requirements to prevent exposure to pathogenic microorganisms.
A catalyst, an application, and a method for preparing 2,5-furanedicarboxylic acid by catalyzing 5-hydroxymethylfurfural in a base-free condition, which include a catalyst having the formula A/MnaBbOx-yVC, wherein A is Pt, Ru, Pd, or Au, B is Co, Ce, Cu, or Ni, a mole ratio of a and b is 1.5-14, and y=0.0-0.4.
A method for predicting performance of LED structure is provided. The prediction method mainly includes: collecting and extracting input feature parameters and output feature parameters of LED structures, and constructing corresponding datasets; preprocessing data in the datasets; constructing a model using a machine learning algorithm, setting structural parameters of the model, and performing initialization training on the model to obtain an initial model; using preprocessed datasets to train and optimize the initial model, thereby obtaining a prediction model; inputting input feature parameters of an LED structure to be predicted into the prediction model, thereby obtaining prediction values of output feature parameters of the LED structure to be predicted. The prediction method can predict the performance of LED structure, has short prediction time, and has high prediction accuracy.
G06F 30/27 - Optimisation, vérification ou simulation de l’objet conçu utilisant l’apprentissage automatique, p. ex. l’intelligence artificielle, les réseaux neuronaux, les machines à support de vecteur [MSV] ou l’apprentissage d’un modèle
33.
INTEGRATED MICRO-LED DISPLAY DEVICE AND DISPLAY PANEL COMPRISING SAME
The present application provides an integrated Micro-LED display device and a display panel comprising same. The integrated Micro-LED display device comprises: a substrate and multiple display pixel units bonded on the substrate. Each display pixel unit comprises a driving chip and a plurality of Micro-LED chips that are independent of each other; a first metal wire and a second metal wire that are used for connecting the display pixel units are respectively provided on a first surface and a second surface of the substrate, and a part of the first metal wire and a part of the second metal wire are connected by means of a plurality of conductive via holes formed in the substrate; the first metal wire and/or the second metal wire each comprise/comprises a positive electrode bus and a negative electrode bus, and the driving chip and at least one bus are respectively arranged on different surfaces of the substrate. By means of the solution, a driving chip and Micro-LED chips that are independent of each other can be bonded onto a circuit substrate in a mass transfer mode to form a display pixel array, thereby achieving large-current driving of the Micro-LED chips, and simultaneously achieving one-to-many integrated driving of the driving chip and the Micro-LED chips.
H01L 25/16 - Ensembles consistant en une pluralité de dispositifs à semi-conducteurs ou d'autres dispositifs à l'état solide les dispositifs étant de types couverts par plusieurs des sous-classes , , , , ou , p. ex. circuit hybrides
H01L 33/62 - Dispositions pour conduire le courant électrique vers le corps semi-conducteur ou depuis celui-ci, p.ex. grille de connexion, fil de connexion ou billes de soudure
G09F 9/33 - Dispositifs d'affichage d'information variable, dans lesquels l'information est formée sur un support, par sélection ou combinaison d'éléments individuels dans lesquels le ou les caractères désirés sont formés par une combinaison d'éléments individuels à semi-conducteurs, p. ex. à diodes
34.
METHOD FOR PREDICTING PERFORMANCE OF SOLAR CELL STRUCTURE
A method for predicting performance of solar cell structure includes: collecting and extracting input feature parameters of solar cell structures and corresponding output feature parameters; establishing corresponding data sets, and preprocessing the data sets according to a known criterion; constructing a model by utilizing a machine learning algorithm, and setting structural parameters and performing initialization training on the model; performing training optimization on the model subjected to setting the structural parameters and performing the initialization training by using a preprocessed training data set to obtain a prediction model; and inputting a preprocessed test data set of a to-be-predicted solar cell structure into the prediction model to obtain predicted values of output feature parameters of the to-be-predicted solar cell structure. The performance of solar cell structure can be rapidly predicted, which is convenient to operate and has a high accuracy.
The present disclosure relates to the technical field of molecular biology and biological pharmaceuticals, and particularly, to use of the Pirin gene and protein in preparing an anti-tumor targeted drug. As new anti-tumor targets, the Pirin gene and protein can be used as the targets for tumor therapies (including but not limited to immunotherapy sensitization), and inhibitors targeting Pirin can effectively enhance the ability of immune cells to kill tumor cells and inhibit the development and progression of tumors. The therapeutic effect and prognosis of patients can be predicted by means of determining Pirin expression level, and drugs targeting Pirin can serve as a new means of tumor-targeted therapy alone or in combination with immunotherapy. The present invention lays a foundation for the combination of tumor-targeted chemotherapeutics with immunotherapies, the enhancement of sensitivity to tumor immunotherapy, and the improvement of immunotherapeutic effects, thereby possessing great prospects.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A method for fast high-resolution multi-parametric quantitative magnetic resonance imaging comprises: designing a fast high-resolution multiple overlapping-echo imaging pulse sequence; determining sampling parameters of the pulse sequence; constructing a deep neural network for reconstructing high-resolution multi-parametric quantitative magnetic resonance images; generating training samples of the deep neural network; using the training samples to train the deep neural network to obtain trained deep neural networks; scanning a real imaging object using the pulse sequence under the sampling parameters to obtain k-space data of the real imaging object; pre-processing the k-space data of the real imaging object to obtain image domain data of the real imaging object; and inputting the image domain data of the real imaging object into the trained deep neural networks for the reconstructing to obtain the high-resolution multi-parametric quantitative magnetic resonance images of the real imaging object.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
G06T 5/10 - Amélioration ou restauration d'image utilisant le filtrage dans le domaine non spatial
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
37.
METHOD FOR SIC STEP FLOW GROWTH BY REGULATING GROWTH MONMOERS USING CHEMICAL POTENTIAL UNDER NON-EQUILIBRIUM CONDITION
A method for SiC high-speed growth by regulating growth monomers using chemical potential under a non-equilibrium condition. The method uses a C-rich process (Si/H2=0.97‰, C/Si=1.55) to achieve a rapid growth of an epitaxial layer. When a relative chemical potential μC of the C source in a growth atmosphere is high, growth monomers adsorbed in advance are SiC molecules in an epitaxial growth, and a height of a growth step is maintained at 1/2 c or 1 c. A rapid growth of the epitaxial growth is achieved, and a better surface roughness and a lower ionized doping concentration are obtained at the same time.
Provided is a separated Coxsackivirus B1 (CVB1). The amino acid at position 84 of a VP1 protein of the CVB1 is lysine (K), the amino acid at position 224 of the VP1 protein is valine (V), and the amino acid at position 232 of a VP3 protein is glycine (G). Also provided is a recombinant virus using the CVB1 as a virus framework and further comprising an exogenous nucleic acid. Also provided is a method for treating a tumor by using the CVB1 or the recombinant virus.
Provided are a fusion protein and a composition, a kit, a granulated antigen, a vaccine, and a pharmaceutical composition comprising same. The present invention also relates to use of the fusion protein and the composition, the kit, and the granulated antigen comprising same in the preparation of a pharmaceutical composition or a vaccine. The granulated antigen is particularly suitable for the production and vaccination of a vaccine and has advantages in the prevention and/or treatment of viral infections.
The present invention provides a composite positive electrode material, a preparation method therefor, and a lithium-ion secondary battery comprising same. The composite positive electrode material comprises: a core layer comprising a positive electrode active material, wherein the positive electrode active material includes uniformly distributed tungsten; and a coating layer comprising phosphorus and tungsten. By means of the composite positive electrode material, the preparation method therefor and the lithium-ion secondary battery comprising same of the present invention, side reactions between the positive electrode active material and an electrolytic solution are reduced, thereby effectively improving the interface stability, improving the cycling performance of the lithium-ion secondary battery, reducing the increase in impedance, and improving the charge/discharge capacity.
An antimicrobial peptide Scyampcin44-63, a formula of the antimicrobial peptide Scyampcin44-63 is C113H188N30O24S2, and an amino acid sequence of the antimicrobial peptide Scyampcin44-63 is SEQ ID NO: 01 with the C-terminus being amidated.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
42.
TRUNCATED RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND USE THEREOF
Provided are a fusion protein, and a nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein. The present invention also relates to a vaccine comprising the fusion protein or the nucleic acid molecule. Furthermore, the present invention also relates to a method for preventing and/or treating RSV infections or diseases and/or symptoms caused by RSV infections by means of using the fusion protein, the nucleic acid molecule and the vaccine.
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
43.
HYDROGEN PREPARATION METHOD BASED ON MICRO-DROPLETS
A hydrogen preparation method based on micro-droplets, relating to the technical field of green energy. The hydrogen preparation method comprises: mixing water and a regulator to obtain an aqueous solution, wherein the regulator is selected from one or more of a nano material, a conductive polymer and an inorganic salt having oxidation-reduction properties; inputting the aqueous solution into a micro-droplet generation device to generate micro-droplets, the size of the micro-droplets being less than or equal to 10 μm, and spontaneously generating hydrogen radicals by means of a strong electric field of double electric layers at a gas-liquid interface of the micro-droplets; compounding the hydrogen radicals to generate hydrogen; and collecting the hydrogen or the hydrogen radicals. By means of the strong electric field at the gas-liquid interface of the micro-droplets, H+ in water molecules on the interface of the aqueous solution obtains electrons to form hydrogen radicals, and two hydrogen radicals are compounded to form hydrogen. The preparation process is simple, green and environmentally-friendly, the added regulator can effectively improve the yield of hydrogen, the preparation process is not limited by a catalyst, and different production process requirements can be met.
C25B 1/04 - Hydrogène ou oxygène par électrolyse de l'eau
C25B 9/00 - Cellules ou assemblages de cellulesÉléments de structure des cellulesAssemblages d'éléments de structure, p. ex. assemblages d'électrode-diaphragmeCaractéristiques des cellules relatives aux procédés
SUN YAT-SEN UNIVERSITY CANCER CENTER (SUN YAT-SEN UNIVERSITY CANCER CENTER HOSPITAL, SUN YAT-SEN (Chine)
SUN YAT-SEN UNIVERSITY (Chine)
Inventeur(s)
Chen, Yixin
Zhang, Xiao
Hong, Junping
Xu, Miao
Wu, Qian
Zhong, Ling
Xia, Ningshao
Abrégé
Provided are an epitope peptide (or a variant thereof) that can be used for preventing or treating an EBV infection, a recombinant protein containing the epitope peptide (or variant thereof) and a carrier protein, and the use of the epitope peptide (or variant thereof) and the recombinant protein. Further provided are an antibody against the epitope peptide, and the use thereof in the detection, prevention and/or treatment of an EBV infection and/or diseases caused by the infection.
The present disclosure discloses a triphenylphosphine-modified sertraline derivative, a prepare method and an application thereof, a structural formula is as follows:
The present disclosure discloses a triphenylphosphine-modified sertraline derivative, a prepare method and an application thereof, a structural formula is as follows:
The present disclosure discloses a triphenylphosphine-modified sertraline derivative, a prepare method and an application thereof, a structural formula is as follows:
wherein n=1, 3, 5, 7, 9 or 11. The present disclosure can be used as an inducer for mitophagy for the prevention and/or treatment of mitophagy-related diseases including tumors and neurodegenerative diseases.
The present application relates to an electronic electroplating chip having a through-silicon via which has a high aspect ratio and a preparation method. The method comprises the following steps: S1: coating a photoresist on a surface of a silicon substrate, and developing and exposing a hole site after photoetching exposure; S2: covering part of the exposed hole site of the silicon substrate by using a passivation layer; S3: etching the bottom surface of the passivation layer, and exposing the silicon substrate corresponding to the bottom surface of the hole site; S4: etching the silicon substrate corresponding to the bottom surface exposing the hole site; S5: repeating steps S2-S4 multiple times to obtain a through-silicon via of a target depth, and cleaning and performing ashing on residual photoresist and passivation substances in the through-silicon via; and S6: depositing an insulating layer, a barrier layer and a seed layer on an inner wall of the through-silicon via by means of an ALD deposition method to obtain a through-silicon via which has a high aspect ratio. Passivation-etching-etching is repeated by means of a three-pulse process to solve the balancing problem of etching and passivation when modifying the process and ensure the stability of the process. Finally, once ALD is selected to carry out a side wall deposition process, it is ensured that the inner side wall of the via has enough coverage capability.
H01L 21/768 - Fixation d'interconnexions servant à conduire le courant entre des composants distincts à l'intérieur du dispositif
H01L 23/48 - Dispositions pour conduire le courant électrique vers le ou hors du corps à l'état solide pendant son fonctionnement, p. ex. fils de connexion ou bornes
H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
47.
METHOD FOR DETECTING PRESENCE OR PROPORTION OF DONOR IN RECEPTOR SAMPLE, AND KIT
A method for detecting SNP sites of a donor-derived sample and a recipient-derived sample, a method for detecting the presence or proportion of a donor in a receptor sample, and a kit for implementing the methods.
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]
A display panel and a preparation method therefor. The preparation method comprises: providing a first substrate (300), one side of the first substrate (300) being provided with a plurality of Micro-LED chips spaced apart; providing a second substrate (201), one side surface of the second substrate (201) being provided with a plurality of conductive layers (206); forming an isolation layer (207) on the second substrate (201), a plurality of opening groups being provided in the isolation layer (207), each opening group comprising a first opening (2071) and a second opening (2072) which expose the surfaces of the conductive layers (206), the width of the first opening (2071) being greater than that of a P-type electrode (304), and the width of the second opening (2072) being greater than that of an N-type electrode (305); forming a first bonding layer (2081) in the first openings (2071), and forming a second bonding layer (2082) in the second openings (2072); and supporting a chip body by using the isolation layer (207), and bonding the N-type electrode (305) to the second bonding layer (2082) while bonding the P-type electrode (304) to the first bonding layer (2081), the P-type electrode (304) being embedded in the first bonding layer (2081), and the N-type electrode (305) being embedded in the second bonding layer (2082).
H01L 27/15 - Dispositifs consistant en une pluralité de composants semi-conducteurs ou d'autres composants à l'état solide formés dans ou sur un substrat commun comprenant des composants semi-conducteurs avec au moins une barrière de potentiel ou une barrière de surface, spécialement adaptés pour l'émission de lumière
H01L 33/14 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les corps semi-conducteurs ayant une structure contrôlant le transport des charges, p.ex. couche semi-conductrice fortement dopée ou structure bloquant le courant
H01L 33/62 - Dispositions pour conduire le courant électrique vers le corps semi-conducteur ou depuis celui-ci, p.ex. grille de connexion, fil de connexion ou billes de soudure
H01L 33/00 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails
H01L 21/67 - Appareils spécialement adaptés pour la manipulation des dispositifs à semi-conducteurs ou des dispositifs électriques à l'état solide pendant leur fabrication ou leur traitementAppareils spécialement adaptés pour la manipulation des plaquettes pendant la fabrication ou le traitement des dispositifs à semi-conducteurs ou des dispositifs électriques à l'état solide ou de leurs composants
49.
OBJECTIVE LENS, OPTICAL IMAGING DEVICE, OPTICAL SYSTEM, AND TEST METHOD OF OPTICAL SYSTEM
An objective lens, an optical imaging device, an optical system, and a test method of the optical system, relating to the field of optical testing. The purpose is to optimize the structure of the objective lens. The objective lens comprises a housing and an optical focusing assembly. The housing comprises a cavity, and the cavity is provided with a first opening and a second opening. The optical focusing assembly is mounted in the cavity, the focal point of the optical focusing assembly is located at the second opening, and the optical focusing assembly is configured to focus light entering the housing from the first opening a to the focal point. The optical focusing assembly in the objective lens focuses light on the basis of one of the reflection principle and the refraction principle.
The present application provides a method for transferring micro flip chips, comprising: providing a driving substrate and a temporary substrate, a plurality of micro flip chips being bonded to one surface of the temporary substrate; forming first bonding members on the surfaces of second electrical connecting members of the micro flip chips facing away from the temporary substrate, the first bonding members being made of a conductive adhesive; transferring the plurality of micro flip chips to the driving substrate, and connecting the second electrical connecting members of the micro flip chips and first electrical connecting members of the driving substrate by means of the first bonding members; testing the plurality of micro flip chips, and determining a defective pixel position of a defective chip on the driving substrate; and irradiating the first bonding member at the defective pixel position with laser, and removing the defective chip. The method can ensure stable bonding of the micro flip chips and the driving substrate, enables original bonding solder joints to continue to be used while preventing the first electrical connecting members from being damaged by laser irradiation, and has high defective chip removal efficiency.
H01L 33/00 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails
H01L 33/48 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les éléments du boîtier des corps semi-conducteurs
H01L 33/62 - Dispositions pour conduire le courant électrique vers le corps semi-conducteur ou depuis celui-ci, p.ex. grille de connexion, fil de connexion ou billes de soudure
H01L 25/075 - Ensembles consistant en une pluralité de dispositifs à semi-conducteurs ou d'autres dispositifs à l'état solide les dispositifs étant tous d'un type prévu dans une seule des sous-classes , , , , ou , p. ex. ensembles de diodes redresseuses les dispositifs n'ayant pas de conteneurs séparés les dispositifs étant d'un type prévu dans le groupe
51.
CATALYST, PREPARATION METHOD THEREFOR AND USE THEREOF
The present invention relates to a catalyst, a preparation method therefor and use thereof, and belongs to the field of catalysts. The catalyst comprises a metal-based active component and a surface metal oxide active component, wherein the metal-based active component comprises at least one of a nickel-based catalyst or a cobalt-based catalyst, and the surface metal oxide active component comprises at least one of a tungsten oxide or a molybdenum oxide deposited on a surface of the metal-based active component. The catalyst may be used for the preparation of a multi-stage amine, which is simple to operate. The catalyst has a high activity in the reductive amination reaction, high safety, high selectivity and good stability; the catalyst can be repeatedly used many times; the catalyst is also beneficial to improving the quality and the quality stability of products and reducing the process cost; moreover, the catalyst has low modification cost, which is beneficial to large-scale production.
B01J 37/18 - Réduction avec des gaz contenant de l'hydrogène libre
B01J 35/00 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général
C07C 209/78 - Préparation de composés contenant des groupes amino liés à un squelette carboné à partir d'amines, par des réactions n'impliquant pas de groupes amino, p. ex. réduction d'amines non saturées, aromatisation ou substitution du squelette carboné à partir de composés carbonylés, p. ex. à partir de formaldéhyde, et d'amines ayant des groupes amino liés à des atomes de carbone de cycles aromatiques à six chaînons, avec formation de méthylène-diarylamines
52.
QUANTUM DOT LIGHT-EMITTING THIN FILM, PREPARATION THEREOF AND USE THEREOF IN WHITE-LIGHT MINI-LED DEVICE
A quantum dot light-emitting thin film, the preparation thereof and the use thereof in a white-light Mini LED device. The quantum dot light-emitting thin film is made of a quantum dot light-emitting material. The quantum dot light-emitting material is prepared by embedding quantum dots into pore channels in the surfaces of mesoporous nanospheres, then wrapping the surfaces with transparent oxide shell layers, and finally embedding the spheres into an organic polymer; and the general chemical formula thereof is: M@N/P@Q, wherein M is quantum dots; @ represents embedding; N is mesoporous nanospheres; / represents core-shell; P is a transparent oxide shell layer; and Q is an organic polymer. The quantum dot light-emitting thin film has high light-emitting stability and brightness and low preparation cost.
C09K 11/02 - Emploi de substances particulières comme liants, revêtements de particules ou milieux de suspension
C09K 11/66 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du germanium, de l'étain ou du plomb
C09K 11/70 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du phosphore
C09K 11/88 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du sélénium, du tellure ou des chalcogènes non spécifiés
H01L 33/26 - Matériaux de la région électroluminescente
53.
SILVER COLLOID ACTIVATION SOLUTION COMPOSITION FOR CHEMICAL COPPER PLATING METALLIZATION ON SURFACE OF POLYMER AND PREPARATION METHOD FOR SILVER COLLOID ACTIVATION SOLUTION COMPOSITION
The present application discloses a silver colloid activation solution composition for chemical copper plating metallization on the surface of a polymer and a preparation method for the silver colloid activation solution composition. A pH is equal to 6-9, the particle size of colloidal silver particles is 5-20 nm, and the silver colloid activation solution composition comprises a soluble silver salt, a first reducing agent, a second reducing agent, a stabilizer, a pH regulator, and deionized water. In the present invention, environmentally-friendly reducing agents and stabilizer are used, the water solubility is good, the preparation method is simple, the cost is low, and environmental friendliness is achieved; the particle size distribution of the silver colloid in the present invention is narrow, the stability is good, and still no precipitation occurs after placement for more than half a year; the force of binding of the present invention to a polymer substrate is good, and the present invention can be used for catalyzing the chemical copper plating metallization process on the surface of a polymer material; after the polymer is activated and subjected to chemical copper plating in the present invention, a copper coating which is compact, continuous and uniform, and has good force of binding to the substrate can be obtained.
An electrochemical nano infrared spectromicroscope and an analysis method. The electrochemical nano infrared spectromicroscope comprises: an electrochemical detection cell (10), the electrochemical detection cell (10) comprising a detection cavity (11) and a wall (12) enclosed to form the detection cavity, the wall (12) comprising an infrared permeable window (121), a sample area (123) being provided on the inner side surface of the infrared permeable window (121), and the sample area (123) being used for placing a sample to be detected (13); a scanning probe microscope system (20), the scanning probe microscope system (20) being configured to interact with said sample (13) located in the sample area (123) by means of a scanning probe (21), and measure a response from the scanning probe (21); and an infrared radiation source (30), the infrared radiation source (30) being configured to emit infrared radiation from the outer side of the infrared permeable window (121) to the sample area (123).
G01N 21/35 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge
G01Q 60/00 - Types particuliers de microscopie à sonde à balayage SPM [Scanning-Probe Microscopy] ou appareils à cet effetComposants essentiels de ceux-ci
G01Q 60/24 - Microscopie à forces atomiques AFM [Atomic Force Microscopy] ou appareils à cet effet, p. ex. sondes AFM
G01Q 60/38 - Sondes, leur fabrication ou leur instrumentation correspondante, p. ex. supports
55.
METHOD FOR TWO-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE DIFFUSION ORDERED SPECTROSCOPY BASED ON DEEP LEARNING
A method for processing two-dimensional (2D) nuclear magnetic resonance (NMR) Diffusion Ordered Spectroscopy (DOSY) based on deep learning comprises constructing a simulated dataset by generating simulated data using a mathematical model based on signal characteristics of the 2D NMR DOSY, generating labels for training a deep learning network model, wherein the labels comprise a first two-dimensional matrix, and two dimensions of the first two-dimensional matrix comprise chemical shift and diffusion coefficients, constructing the deep learning network model and setting training parameters of the deep learning network model, training the deep learning network model using the simulated dataset, and testing the deep learning network model.
G01N 24/08 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin en utilisant la résonance magnétique nucléaire
A peptide disinfectant for preventing coronaviruses is provided. The peptide disinfectant for preventing coronaviruses comprises an active ingredient of the peptide disinfectant comprises mixed peptides comprising a first peptide (SEQ ID NO. 01), a second peptide (SEQ ID NO. 02), and a third peptide (SEQ ID NO. 03).
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A01N 25/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles
A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
57.
PREPAKAGED POLYMERASE CHAIN REACTION (PCR) REAGENT FOR NUCLEIC ACID AMPLIFICATION AND METHOD THEREOF
A prepackaged polymerase chain reaction (PCR) reagent for nucleic acid amplification and a method thereof are provided. A PCR reagent includes an antifreeze protein and an antifreeze protein antibody.
Provided are a newly designed HIV-1 Env trimer protein, and an HIV-1 pseudovirus and virus expressing the Env trimer protein, and the use thereof for the prevention and/or treatment of HIV infection.
An adjuvant containing zinc aluminum risedronate, an immunogenic composition comprising the adjuvant and an immunogen, and uses of the adjuvant and the immunogenic composition.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
Disclosed in the present invention are a low-copper-salt weakly-alkaline electronic copper electroplating liquid and a use thereof. The low-copper-salt weakly-alkaline electronic copper electroplating liquid is composed of deionized water, an inorganic bivalent copper salt, a coordination agent, a pH buffering agent, and a leveling agent. According to the present invention, an organic matter containing hydroxyl and/or carboxyl serves as a bivalent copper ion coordination agent, and the pH buffering agent and the leveling agent which have specific compositions and content are used, such that compact filling of a PCB blind hole is achieved; and the present invention has the characteristics of being simple in composition, low in copper salt concentration, weakly-alkaline, low in corrosivity, and easy to regulate and control.
C25D 3/38 - Dépôt électrochimiqueBains utilisés à partir de solutions de cuivre
C25D 7/00 - Dépôt électrochimique caractérisé par l'objet à revêtir
H05K 3/18 - Appareils ou procédés pour la fabrication de circuits imprimés dans lesquels le matériau conducteur est appliqué au support isolant de manière à former le parcours conducteur recherché utilisant la technique de la précipitation pour appliquer le matériau conducteur
61.
B2M-GLUN1 BLOCKING PEPTIDE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
Provided are a drug for reducing a B2M level in a human brain, a drug for reducing a level of an amyloid precursor protein in the human brain, a drug for inhibiting the binding of GluN1 and B2M in the human brain, or a drug for repairing synaptic damage caused by the increase of B2M in the human brain.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
62.
ACID SULFATE ELECTROPLATING COPPER COMBINATION ADDITIVE FOR DENSE FILLING OF PCB THROUGH HOLE METAL
Disclosed in the present invention is an acid sulfate electroplating copper combination additive for dense filling of PCB through hole metal. The additive is made up of a bridger, a carrier, a refiner, and a leveler having mass ratios of 10-100:50-1500:0.1-20:0.1-100. In the present invention, an inorganic substance for supplying halogen anions is used as the bridger, a polyol, a polyether, or a polyester compound is used as the carrier, a sulfur-containing compound is used as the refiner, and a primary/secondary/tertiary amine or quaternary ammonium salt is used as the leveler, which, in combination with specific high-copper low-acid, temperature, plating solution stirring, air blowing, cathode moving, and electroplating current density conditions, achieve dense filling of PCB through holes.
Disclosed is design optimization method of the structure considering centrifugal loads and stress constraints. Compared with the prior art, this application improves the method for obtaining the relaxation coefficient c, including the calculation of the second predicted maximum stress based on the predicted stress method from steps S9.1 to S9.8. The influence of the existence of jagged boundaries and gray densities on the calculation of the structural stress field is reduced. The most important thing is to decide whether to use linear penalty or nonlinear penalty for the elastic modulus of each element according to the ratio of the number of elements with design variables less than 0.1 and greater than 0.9 to the total number of elements. Introducing the predicted maximum stress can make full use of the allowable stress of materials, improve the quality of optimization design, and obtain a design scheme with a lighter mass.
G06F 30/13 - Conception architecturale, p. ex. conception architecturale assistée par ordinateur [CAAO] relative à la conception de bâtiments, de ponts, de paysages, d’usines ou de routes
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A23K 50/80 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les animaux aquatiques, p. ex. pour les poissons, les crustacés ou les mollusques
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
65.
Method for preparing anisotropic cellulose-based hydrogel
4 nanoparticles on a surface of the cellulose-based nanosheets by a deposition method to obtain magnetic cellulose-based nanosheets; and forming the anisotropic cellulose-based hydrogel using the magnetic cellulose-based nanosheets by a polymerization method.
C08B 15/06 - Dérivés contenant des éléments autres que carbone, hydrogène, oxygène, halogènes ou soufre contenant de l'azote
C08F 251/02 - Composés macromoléculaires obtenus par polymérisation de monomères sur des polysaccharides ou leurs dérivés sur la cellulose ou ses dérivés
66.
BETA 2-MICROGLOBULIN BLOCKING PEPTIDE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
The present invention belongs to the field of biomedicine, and relates to a beta 2-microglobulin blocking peptide, and a pharmaceutical composition and the use thereof. In particular, the present invention relates to an isolated polypeptide, which is a polypeptide as shown in SEQ ID NO: 3 or a truncated fragment of the polypeptide as shown in SEQ ID NO: 3, wherein the truncated fragment comprises a polypeptide as shown in SEQ ID NO: 8. The isolated polypeptide of the present invention can effectively prevent and treat AD or cognitive impairment caused by AD, and has good application prospects.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
67.
PHOTOLITHOGRAPHY METHOD FOR PREPARING SEMICONDUCTOR VERTICAL CROSS-SECTIONAL STRUCTURE
A photolithography method for preparing a semiconductor vertical cross-sectional structure. A partition member (3) is designed according to a photolithographic pattern, the partition member (3) comprises a cover plate (31), the cover plate (31) has a shielding area (31a) and hollow areas (31b), and the periphery of each hollow area (31b) extends vertically downward to form a partition plate (32); after a photoresist (2) is coated on the surface of a semiconductor substrate (1), the partition member (3) is placed on the photoresist (2), the partition plates (32) are embedded in the photoresist (2) to physically isolate the portions of the photoresist (2) corresponding to the shielding area (31a) and the hollow areas (31b), and then exposure, development, and subsequent etching processes are performed. The partition member (3) physically isolates the portions of the photoresist (2) requiring exposure, thereby realizing a vertical cross section of 90 degrees, and realizing a low-cost and high-precision photolithography process.
G03F 1/00 - Originaux pour la production par voie photomécanique de surfaces texturées, p. ex. masques, photomasques ou réticulesMasques vierges ou pellicules à cet effetRéceptacles spécialement adaptés à ces originauxLeur préparation
G03F 7/00 - Production par voie photomécanique, p. ex. photolithographique, de surfaces texturées, p. ex. surfaces impriméesMatériaux à cet effet, p. ex. comportant des photoréservesAppareillages spécialement adaptés à cet effet
68.
USE OF MANNOSE IN INHIBITING PYROPTOSIS OR RELIEVING TOXIC AND SIDE EFFECTS OF CHEMOTHERAPY DRUG
Provided is use of mannose in inhibiting pyroptosis or relieving toxic and side effects of a chemotherapy drug, which relates to the field of medical science and technologies. Mannose inhibits pyroptosis induced by a chemotherapy drug, such that toxic and side effects caused by the chemotherapy drug on the intestinal tract and the kidney are relieved, and meanwhile, a treatment effect of the chemotherapy drug on a tumor is not affected. Mannose can be used for preparing a drug, a kit, a pharmaceutical composition or a health care product for inhibiting pyroptosis or relieving toxic and side effects of the chemotherapy drug. Side effects caused by the chemotherapy drug on the kidney and the intestinal tract can be relieved. Mannose can be used as a supplementary drug clinically, the toxic and side effects of the chemotherapy drug are relieved as much as possible while the curative effect of the chemotherapy drug is ensured, the physical and psychological health of the patient is improved, and meanwhile, the tumor inhibition effect of the chemotherapy drug is not affected. Therefore, a new choice for clinical medication is provided for a cancer patient.
Provided are a method for assaying a specific IgM antibody and a total antibody for the 2019 novel coronavirus (2019-nCOV), a method for determining whether subjects are infected with 2019-nCOV, and a virus antigen and a kit for carrying out the above-mentioned detection.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
70.
Engineered radioactive polymeric microsphere, and preparation and application thereof
An engineered radioactive polymeric microsphere, and a preparation and application thereof. The preparation method includes: adding a styrene monomer and a disperser and/or a crosslinker into a medium, followed by feeding of nitrogen or helium and stirring to obtain a first reaction mixture; heating the first reaction mixture, and adding an initiator, followed by reaction under stirring at a constant temperature to obtain a second reaction mixture; subjecting the second reaction mixture to washing with ethanol and water, and vacuum drying to obtain a crude polymeric microsphere; subjecting the crude polymeric microsphere to radiation-induced graft polymerization with a functional monomer to obtain the functionalized polymeric microsphere; and exposing the functionalized polymeric microsphere to a radionuclide to prepare the engineered radioactive polymeric microsphere.
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
C08F 257/02 - Composés macromoléculaires obtenus par polymérisation de monomères sur des polymères de monomères aromatiques tels que définis dans le groupe sur des polymères de styrène ou de styrène substitué par des groupes alkyle
The present application belongs to the technical field of biomedicine, and more particularly, relates to an antibody or an antigen-binding fragment thereof capable of specifically binding to p-tau 217, and a multi-specific molecule, a pharmaceutical composition, and a kit comprising same. The present application further relates to use of the antibody or the antigen-binding fragment thereof in preparing a kit or a drug. A monoclonal antibody (for example, 2A7 antibody) according to the present application has a high clinical application value in the detection and prevention of AD and the treatment of AD and other tau protein diseases.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
72.
POLYARYL CARBOXYLIC FULLERENE DERIVATIVE AND USE THEREOF IN ANTI-CORONAVIRUS INFECTION
XIAMEN FUNANO NEW MATERIAL TECHNOLOGY CO., LTD. (Chine)
Inventeur(s)
Xie, Suyuan
Zhu, Changfeng
Zhang, Qianyan
Zheng, Lansun
Xu, Piaoyang
Yang, Tongzong
Deng, Linlong
Tan, Yuanzhi
Zhu, Sheng
Abrégé
A polyaryl carboxylic fullerene derivative and its use in anti-coronavirus infection are disclosed. Specifically, a compound shown in formula A: fullerene-RR1R2R3R4R5 formula A, or a stereoisomer, prodrug, pharmaceutically acceptable salt, or pharmaceutically acceptable solvate of the compound is provided. The compound or a derivative thereof has promising application prospects in anti-coronavirus infection.
C07C 57/50 - Composés non saturés comportant des groupes carboxyle liés à des atomes de carbone acycliques contenant des cycles aromatiques à six chaînons et d'autres cycles, p. ex. acide cyclohexylphénylacétique contenant des systèmes cycliques condensés
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
Disclosed in the present invention is an early auxiliary diagnostic kit for Rett syndrome, comprising a library construction assembly and a nanopore sequencing chip for sequencing a library constructed by the library construction assembly, wherein the library construction assembly comprises Cas9 nuclease and a gRNA group, and the gRNA group comprises a MeCP2 gRNA group, a CDKL5 gRNA group, and a FOXG1 gRNA group.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
The present invention belongs to the field of virology, in particular to the field of hepatitis B virus treatment. Provided are a model and a method for screening HBV cccDNA inhibitors. According to the screening model and the method, the detection of a split luciferase is used as an alternative index ofHBV cccDNA detection, and a cccDNA-targeted drug can be screened in high throughput.
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
75.
TRANSMISSION ELECTRON MICROSCOPE HIGH-RESOLUTION IN SITU FLUID FREEZING CHIP AND PREPARATION METHOD THEREOF
A transmission electron microscope high-resolution in situ fluid freezing chip includes a lower chip and an upper chip. The lower chip is provided with a support layer, a freezing layer, an insulating layer, an opening, and a center window. The freezing layer is provided with contact electrodes, semiconductor films, and a conductive metal film. The center window is surrounded by the conductive metal film; the contact electrodes are disposed at an edge of the chip. One ends of the semiconductor films are lapped on the conductive metal film, and the other ends are lapped on the electrodes. In the outer edge of the conductive metal film, silicon is etched to form the opening. The support layer covers the opening. The conductive metal film is disposed on the support layer. A plurality of holes are provided in the center window.
H01J 37/26 - Microscopes électroniques ou ioniquesTubes à diffraction d'électrons ou d'ions
H10N 10/852 - Matériaux actifs thermoélectriques comprenant des compositions inorganiques comprenant du tellure, du sélénium ou du soufre
G01N 23/04 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en transmettant la radiation à travers le matériau et formant des images des matériaux
H01L 23/38 - Dispositifs de refroidissement utilisant l'effet Peltier
The present invention relates to the field of immunology and the field of molecular virology, in particular to the field of prevention and treatment of varicella-zoster viruses. Specifically, the present invention relates to a truncated varicella-zoster virus gE protein (or a variant thereof) capable of soluble expression in an Escherichia coli expression system, and use thereof in preventing and/or treating varicella-zoster virus infections.
An electroplating clamp, and an assembly line capable of vertical rack electroplating and horizontal rotating electroplating, which relate to the technical field of electroplating clamps. The electroplating clamp comprises a support plate and a sealing member, wherein the support plate is provided with a cavity in a thickness direction thereof; a substrate is placed on the support plate and shields a side edge of the cavity; a conductive assembly for coming into conductive contact with the substrate is mounted on the support plate; the sealing member comprises a sealing plate for shielding the substrate and a driving member for driving the sealing plate to approach or move away from the support plate; and a first sealing ring and a second sealing ring are arranged between the support plate and the sealing member. When the sealing plate abuts against the support plate, the first sealing ring is sandwiched between the support plate and the sealing plate, and the first sealing ring surrounds the periphery of the substrate; and the second sealing ring is sandwiched between the support plate and the substrate, and the second sealing ring is located on an inner side of the substrate. The electroplating clamp and the assembly line capable of vertical rack electroplating and horizontal rotating electroplating can improve the sealing of a non-electroplating area of a substrate, and thus improve the electroplating quality.
Provided is a cell-penetrating peptide, which can deliver a variety of biological macromolecules, such as proteins, antibodies, nucleic acids and so on into cells across a membrane. In addition, further provided are a fusion protein, conjugate and complex containing the cell-penetrating peptide, and a use of the cell-penetrating peptide.
Disclosed are a triphenylphosphine-modified sertraline derivative, a preparation method therefor, and use thereof. The triphenylphosphine-modified sertraline derivative is represented by structural formula (I), wherein n = 1, 3, 5, 7, 9, or 11. The derivative disclosed herein can be used as a mitophagy inducer for preventing and/or treating a mitophagy-related disease, including tumors and neurodegenerative diseases.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
80.
System and method of capturing three-dimensional human motion capture with LiDAR
Described herein are systems and methods for training machine learning models to generate three-dimensional (3D) motions based on light detection and ranging (LiDAR) point clouds. In various embodiments, a computing system can encode a machine learning model representing an object in a scene. The computing system can train the machine learning model using a dataset comprising synchronous LiDAR point clouds captured by monocular LiDAR sensors and ground-truth three-dimensional motions obtained from IMU devices. The machine learning model can be configured to generate a three-dimensional motion of the object based on an input of a plurality of point cloud frames captured by a monocular LiDAR sensor.
Provided is a functional subgroup of umbilical cord mesenchymal stem cells that has a high-expression marker on the surface of cells. The marker not only comprises widely recognized CD105, CD73 and CD90, but also comprises newly discovered CXCR4 and CD271. Also provided are a flow cytometric sorting method for the functional subgroup of umbilical cord mesenchymal stem cells, an immunosuppressive composition comprising the functional subgroup of umbilical cord mesenchymal stem cells, and the use thereof. The functional subgroup of umbilical cord mesenchymal stem cells provides a new therapeutic approach for accurately treating immune inflammatory diseases using stem cells.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
A61K 35/51 - Cordon ombilicalSang de cordon ombilicalCellules souches ombilicales
G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
82.
SYSTEM AND METHOD OF CAPTURING THREE-DIMENSIONAL HUMAN MOTION CAPTURE WITH LIDAR
Described herein are systems and methods for training machine learning models to generate three-dimensional (3D) motions based on light detection and ranging (LiDAR) point clouds. In various embodiments, a computing system can encode a machine learning model representing an object in a scene. The computing system can train the machine learning model using a dataset comprising synchronous LiDAR point clouds captured by monocular LiDAR sensors and ground-truth three-dimensional motions obtained from IMU devices. The machine learning model can be configured to generate a three-dimensional motion of the object based on an input of a plurality of point cloud frames captured by a monocular LiDAR sensor.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
Described herein are systems and methods of capturing motions of humans in a scene. A plurality of IMU devices and a LiDAR sensor are mounted on a human. IMU data is captured by the IMU devices and LiDAR data is captured by the LiDAR sensor. Motions of the human are estimated based on the IMU data and the LiDAR data. A three-dimensional scene map is built based on the LiDAR data. An optimization is performed to obtain optimized motions of the human and optimized scene map.
Described herein are systems and methods of capturing motions of humans in a scene. A plurality of IMU devices and a LiDAR sensor are mounted on a human (402). IMU data is captured by the IMU devices and LiDAR data is captured by the LiDAR sensor (404). Motions of the human are estimated based on the IMU data and the LiDAR data (406). A three-dimensional scene map is built based on the LiDAR data (408). An optimization is performed to obtain optimized motions of the human and optimized scene map (410).
G06F 3/0346 - Dispositifs de pointage déplacés ou positionnés par l'utilisateurLeurs accessoires avec détection de l’orientation ou du mouvement libre du dispositif dans un espace en trois dimensions [3D], p. ex. souris 3D, dispositifs de pointage à six degrés de liberté [6-DOF] utilisant des capteurs gyroscopiques, accéléromètres ou d’inclinaison
G01S 17/89 - Systèmes lidar, spécialement adaptés pour des applications spécifiques pour la cartographie ou l'imagerie
85.
EPITOPE PEPTIDE AND ANTIBODY FOR TREATING HBV INFECTION AND RELATED DISEASES
The present invention relates to the field of molecular virology and immunology, in particular to the field of hepatitis B virus (HBV) infection treatment. In particular, the present invention relates to an epitope peptide (or a variant thereof) capable of treating a hepatitis B virus infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and an antibody (e.g. a nanobody) for the epitope peptide. The epitope peptide and antibody of the present invention can be used to prevent and/or treat HBV infection or a disease related to HBV infection (e.g. hepatitis B), for reducing the serum level of HBV DNA and/or HBsAg in a subject (e.g. a human), or for activating a subject (e.g. a chronic HBV infected person or a chronic hepatitis B patient) against HBV humoral immune response.
The present invention relates to a task amplification-based transfer attack method and apparatus. A corresponding adversarial sample is iteratively generated for each clean sample; during each iteration process, an attack task is constructed from two aspects of data amplification and model amplification; after the attack task is constructed, the task is divided into a support set and a query set; according to the core concept of meta learning, a temporary disturbance is then first generated on the support set, and fine adjustment is then performed on the temporary disturbance on the query set; and a final disturbance update is jointly determined by gradients on the support set and the query set. In this way, an adversarial disturbance can be fully generalized on a constructed task, without overfitting a single image mode or a single surrogate model.
The present invention belongs to the field of biomedicine, and relates to a SARS-CoV-2 spike protein variant, a pharmaceutical composition and the use thereof. Specifically, the present invention relates to an isolated polypeptide having an amino acid sequence as shown in any one of SEQ ID NOs: 1-27. The polypeptide of the present invention can simulate broad-spectrum neutralizing antibodies against existing different COVID-19 variant strains, and has a good protection effect on both a SARS-CoV-2 prototype strain and variant strain.
The present application relates to the field of antiviral treatment of hepatitis B, and specifically relates to the use of a compound represented by formula I in treatment against HBV virus.
The present application relates to the field of antiviral treatment of hepatitis B, and specifically relates to the use of a compound represented by formula I in treatment against HBV virus.
The present application provides a photoexcitation-free temperature sensing material, a preparation method, and a temperature sensing method. The photoexcitation-free temperature sensing material has a general chemical formula of (SrxM1-x)1-y-zZnSO:Tby,Euz, wherein 0≤x≤1, 0
G01K 11/20 - Mesure de la température basée sur les variations physiques ou chimiques, n'entrant pas dans les groupes , , ou utilisant des matériaux thermo-luminescents
C09K 11/77 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant des métaux des terres rares
C09K 11/02 - Emploi de substances particulières comme liants, revêtements de particules ou milieux de suspension
C08K 3/30 - Composés contenant du soufre, du sélénium ou du tellure
90.
Laser conformal manufacturing method of flexible sensor
A laser conformal manufacturing method of a flexible sensor comprises: obtaining morphology data of a curved surface, and constructing a Standard Triangle Language (STL) model of the curved surface; introducing into a 3D modeling software, and combining the curved surface with a clamper holder; manufacturing to obtain the clamper with the curved surface; coating material to be manufactured on a 3D curved surface of the clamper with the curved surface; positioning to a processing platform of a laser device; constructing a model of a pattern to be manufactured by laser based on the STL model of the curved surface, and constructing an STL model or a dwg model of the pattern to be manufactured; introducing into the laser device, turning on the laser device, and running a 3D dynamic focus system; repeating the steps 4-8, and stripping the flexible sensor from the 3D curved surface.
B29C 64/386 - Acquisition ou traitement de données pour la fabrication additive
B23K 26/046 - Focalisation automatique du faisceau laser
B33Y 50/02 - Acquisition ou traitement de données pour la fabrication additive pour la commande ou la régulation de procédés de fabrication additive
B23K 26/359 - Travail par rayon laser, p. ex. soudage, découpage ou perçage pour le traitement de surface en formant une ligne ou un motif linéaire, p. ex. une ligne en pointillés d'amorce de rupture
B23K 37/04 - Dispositifs ou procédés auxiliaires non spécialement adaptés à un procédé couvert par un seul des autres groupes principaux de la présente sous-classe pour maintenir ou mettre en position les pièces
91.
RECOMBINANT VECTOR OF THERMOLABILE UNG FUSED PROTEIN AND AN EXPRESSING AND PURIFYING METHOD
A recombinant vector of a thermolabile UNG fused protein and an expressing and purifying method are provided. The method comprises cloning a Cod UNG genetic sequence to a pCold-SUMO vector to construct a recombinant vector pCold-SUMO-Cod UNG, transforming to E. coli BL21 (DE3) competent cells, transforming and expressing molecular chaperone plasmids pG-Tf2, and inducing the expression at a low temperature to obtain a soluble SUMO-Cod UNG fused protein.
Disclosed are an integrated polymer-derived ceramic thin-film sensor prepared using combined laser pyrolysis and additive manufacturing, and a preparation method therefor. A strain sensitive layer with an excellent conductivity is obtained by means of the method of using a metal component or an insulating material as a substrate, forming a PDC-doped composite insulating film layer with a high compactness, high insulativity and high temperature resistance on a surface of the metal component by means of a layer-by-layer laser pyrolysis additive manufacturing technique, directly writing a sensitive grid of a PDC-doped filler onto the composite insulating film layer by means of a Weissenburg direct-write process, and then performing laser pyrolysis enhanced PDC graphitization; therefore, the laser in-situ additive integrated manufacturing of the PDC material-based high insulating film layer, the PDC material-based sensitive grid with an excellent conductivity, and the metal substrate is created, the laser process flow of conversions among "liquid-solid-function" of a PDC composite material is achieved, and the thin-film sensor is successfully applied to metal material strain sensors.
G01B 7/16 - Dispositions pour la mesure caractérisées par l'utilisation de techniques électriques ou magnétiques pour mesurer les déformations dans un solide, p. ex. au moyen d'une jauge de contrainte à résistance
The present invention relates to the field of immunology and molecular virology, and in particular relates to the field of the prevention and treatment of RSV. Specifically, provided are a monoclonal antibody capable of specifically binding to a new epitope between an Ø epitope and a V epitope on a pre-F protein or a new epitope between an II epitope and a V epitope, and the use thereof in the detection, prevention and/or treatment of RSV infections and/or diseases caused by the infections.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
94.
INTEGRATED POLYMER-DERIVED CERAMIC THIN-FILM SENSOR PRODUCED BY LAYSER PYROLYSIS AND ADDITIVE MANUFACTURING AND FABRICATION METHOD THEREOF
An integrated polymer-derived ceramic (PDC) thin-film sensor produced by laser pyrolysis and additive manufacturing and a fabrication method thereof are provided. Using a metal component or an insulating material as a substrate, a PDC-doped composite insulating film layer with high density, high insulation, and high temperature resistance is formed by a layer-by-layer laser pyrolysis and additive manufacturing on the surface of the metal component, and a strain sensitive layer with excellent electrical conductivity is obtained by Weissenberg direct writing process PDC-doped filler sensitive grid on the composite insulating film layer and laser pyrolysis enhancing graphitization of PDC. In this way, the in situ integrated laser fabrication of highly insulating film layer, sensitive grid with excellent electrical conductivity, and metal substrate based on PDC materials is developed, which achieves the laser processing of “liquid-solid-function” transformation of PDC composites and allows the successful use thereof in strain sensing of metallic materials.
C04B 35/524 - Produits céramiques mis en forme, caractérisés par leur compositionCompositions céramiquesTraitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base de non oxydes à base de carbone, p. ex. graphite obtenus à partir de précurseurs polymères, p. ex. carbone vitreux
C04B 35/626 - Préparation ou traitement des poudres individuellement ou par fournées
C04B 41/00 - Post-traitement des mortiers, du béton, de la pierre artificielle ou des céramiquesTraitement de la pierre naturelle
The present invention relates to the field of immunology and molecular virology, and in particular relates to the field of the prevention and treatment of RSV. Specifically, provided are a monoclonal antibody capable of specifically binding to a new epitope between an Ø epitope and a V epitope on a pre-F protein or a new epitope between an II epitope and a V epitope, and the use thereof in the detection, prevention and/or treatment of RSV infections and/or diseases caused by the infections.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
A61P 31/14 - Antiviraux pour le traitement des virus ARN
96.
METHOD AND APPARATUS FOR EXPANDING ERASURE CODE STORAGE SYSTEM
Disclosed in the present invention are a method and apparatus for expanding an erasure code storage system. The method comprises: determining data in a storage system, encoding the data, dispersedly storing the data in nodes, and obtaining spatial position distribution information of the nodes; determining the number of newly added nodes on each stripe on the basis of expansion demand information, and determining expansion node information on each stripe on the basis of the number of newly added nodes and the spatial position distribution information, wherein each stripe comprises a data block and a check block which have an encoding relationship; determining an expansion group on the basis of the expansion node information and the rule of the least common multiple, and splitting the expansion group, so as to obtain a target group comprising a plurality of selected stripes; and executing an expansion algorithm on the target group, so as to obtain a corresponding target expanded group, wherein the target expanded group comprises an expanded data block and an expanded check block. On the basis of the method, the expansion efficiency of an erasure code storage system can be improved.
G06F 11/10 - Détection ou correction d'erreur par introduction de redondance dans la représentation des données, p. ex. en utilisant des codes de contrôle en ajoutant des chiffres binaires ou des symboles particuliers aux données exprimées suivant un code, p. ex. contrôle de parité, exclusion des 9 ou des 11
97.
FLUORESCENCE ANALYSIS METHOD FOR DETERMINING LITHIUM IONS BY USING EMPTY-SHELL PHTHALOCYANINE AS MOLECULAR PROBE
A fluorescence analysis method for determining lithium ions by using empty-shell phthalocyanine as a molecular probe. The method comprises the following specific steps: first adding an alkaline organic medium to a series of reactors, and then adding a phthalocyanine organic solution with the same volume thereto; then sequentially adding lithium-ion organic solutions with increasing concentrations; and after the volume of the reaction system is constant, placing same aside for a reaction, scanning the fluorescence spectrum of the reaction system, and measuring the relative fluorescence intensities at fluorescence peaks. The determination method has a high sensitivity, a strong specificity, a good linear response, a good stability and a high practicability; the determination wavelength is in the long-wave region of visible light, which gives full play to the advantages of the long-wave fluorescent probe; and the determination system has a small photobleaching effect and can effectively eliminate the interference of background fluorescence and scattered light that may exist in a sample.
Disclosed are a fusion protein probe and a cell model for screening a blocking agent of coronavirus infections, a screening system comprising same, and a method of using the screening system for screening a blocking agent of coronavirus infections. The screening system and method do not involve live viruses, are simple and convenient to operate, have a high accuracy, are suitable for high throughput screening, and are of great significance for the development of coronavirus neutralizing antibodies, preventive vaccines, and small molecule drugs.
C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
99.
MICROFLUIDIC CHIP AND MICROFLUIDIC CHIP TESTING SYSTEM
A microfluidic chip and a microfluidic chip testing system. The microfluidic chip comprises: a storage member (1) on which a recess (11) is provided, at least two storage chambers (12) being provided around the recess (11); a base (2), disposed at an end of the storage member (1) facing away from the recess (11), a reaction chamber (21) being provided on the base; and a valve (3) disposed in the recess (11), the valve (3) being configured to operably put any one of the at least two storage chambers (12) in communication with the reaction chamber (21). By means of operating the valve (3), a solution in any storage chamber (12) can be guided into the reaction chamber (21), or a solution in the reaction chamber (21) can be guided to any storage chamber (12), thereby implementing solution transfer.
A microfluidic chip and a microfluidic chip testing system. The microfluidic chip comprises: a storage member (1) on which a recess (11) is provided, at least two storage chambers (12) being provided around the recess (11); a base (2), disposed at an end of the storage member (1) facing away from the recess (11), a reaction chamber (21) being provided on the base; and a valve (3) disposed in the recess (11), the valve (3) being configured to operably put any one of the at least two storage chambers (12) in communication with the reaction chamber (21). By means of operating the valve (3), a solution in any storage chamber (12) can be guided into the reaction chamber (21), or a solution in the reaction chamber (21) can be guided to any storage chamber (12), thereby implementing solution transfer.
